Shanghai researchers have achieved a landmark advance in gene therapy for neurodevelopmental disorders, publishing their findings in Nature on February 18, 2026. Led by teams from Shanghai Jiao Tong University School of Medicine (SJTU SOM) and collaborators at Fudan University and the Chinese Academy of Sciences, the study demonstrates the first in vivo base editing of the Chd3 gene in the brain, rescuing autism-like behaviors in a mouse model of Snijders Blok–Campeau syndrome (SNIBCPS). This precise single-nucleotide correction restores protein function without double-strand breaks, opening doors to treatments for genetic brain conditions affecting millions worldwide, including in China where autism spectrum disorder (ASD) prevalence hovers around 0.7–1% among children.
SNIBCPS, a rare chromatin-remodeling disorder caused by de novo mutations in CHD3 (chromodomain helicase DNA-binding protein 3), leads to intellectual disability, social deficits, repetitive behaviors, and motor impairments mimicking ASD traits. The recurrent p.R1025W variant accelerates CHD3 degradation, disrupting neural development. With over 60 known cases globally and rising awareness in China, where neurodevelopmental disorders impact roughly 10 million children, this breakthrough from SJTU's Brain and Behavioral Research Unit at Xinhua Hospital signals China's rising prowess in precision medicine.
Unraveling CHD3's Role in Brain Development
CHD3, part of the NuRD complex, regulates chromatin structure essential for gene expression during neurogenesis. Mutations like R1025W trigger ubiquitin-mediated degradation, reducing protein levels in prefrontal cortex, hippocampus, and other regions critical for cognition and social behavior. Researchers at SJTU SOM created a humanized mouse model (Chd3hR1025W/+) via CRISPR knock-in, faithfully recapitulating human symptoms: reduced ultrasonic vocalizations (fewer complex calls), impaired novel object recognition, social avoidance in three-chamber tests, excessive marble-burying/grooming, hypotonia (tail suspension deficits), and gait abnormalities.
This model, validated through RNA-seq (downregulated neurodevelopmental pathways) and ATAC-seq (altered chromatin at ASD-linked loci like Nlgn4l), provides a platform for testing therapies. In China, where ASD diagnosis rates are climbing—urban prevalence at 0.239% vs. rural 0.07% per recent meta-analyses—such models are vital for addressing underdiagnosis and limited interventions.
- Key phenotypes: Social deficits (P=0.0004 preference index), cognitive impairments (shorter Barnes maze latency post-editing), motor rescue (improved rotarod P=0.0035).
- Molecular fix: Editing restores CHD3 dosage, upregulating synaptic genes (Padj=3.73×10-8).
Innovative TeABE: A Safer Base Editor for the Brain
The core innovation is TeABE (TadA-embedded adenine base editor), an optimized ABE converting A•T to G•C without DSBs. Delivered via dual AAV (split-intein reconstitution for large payload), it targets the R1025W mutation (C•G to T•A correction). Optimized TeABE-1248 narrows the editing window (A9–A14), minimizing bystanders (2–3% at A13) vs. standard ABEs.
Intravenous or intracerebroventricular injection achieved 10–15% on-target editing brain-wide, with >80% corrected alleles. GUIDE-seq confirmed <1% off-targets. Step-by-step: (1) sgRNA design pairs with ABE for precise PAM; (2) Dual AAV halves (N/ C-terminal) reassemble via intein; (3) Neuronal transduction (30–70%); (4) Editing restores arginine codon, halting degradation.
This surpasses traditional CRISPR, avoiding indels. SJTU's GMP facilities and Fudan collaborations position Shanghai as a gene editing hub, with centers like ShanghaiTech's Gene Editing Center accelerating translation.Read the full Nature paper.
Behavioral Transformations: From Model to Hope
Treated mice showed profound recovery. Socially, stranger preference rose significantly; cognitively, exploration time in novel objects normalized; repetitively, burying/grooming dropped; motor-wise, grip strength, stride length, and balance improved. No anxiety changes (elevated plus maze), indicating specificity.
These align with SNIBCPS human traits, validated by ultrasonic vocalization analysis—fewer calls pre-treatment, restored post. Protein immunofluorescence confirmed CHD3 recovery in cortex/hippocampus.
Safety First: Primate Validation and Low Risks
In nonhuman primates, intrathecal dual AAV yielded 70–80% editor reconstitution, widespread neuronal editing (>30% transduction). No adverse effects observed, with bystander/off-target <1%. This mitigates AAV immunogenicity concerns, paving for clinical NCT06860672 at SJTU (dual AAV for CHD3-R1025W kids).
China's regulatory advances (NMPA approvals for base editors) and Shanghai's biotherapy cores support rapid trials. Compared to DSB editors, base editing's precision suits postnatal brain therapy.
China's Neurodevelopmental Burden and Research Momentum
China reports ~7–10 million ASD cases, with ADHD at 6–8%. Urban-rural disparities persist, straining resources. Shanghai leads: SJTU SOM's pediatric research unit integrates clinics/models; Fudan Children's Hospital handles diagnostics; CAS Shanghai provides molecular tools.
Stats: 2023 meta-analysis—ASD 7/1000, rising; Shanghai caregiver surveys show ADHD 12.6%. Gene therapies fill gaps where behavioral interventions fall short.
- Benefits: Early correction prevents lifelong disability.
- Risks: Delivery efficiency (optimize LNPs), durability (monitor 6–12 months).
Shanghai Universities: Powerhouses of Gene Editing
SJTU SOM's MOE Key Lab pioneers in vivo editing; ShanghaiTech GEC develops IP tools; Fudan integrates pediatrics/genomics. Facilities: GMP labs, AAV production, primate centers. Collaborations with CAS fuel translation—e.g., prior ASD base editing (2023).
This Nature paper elevates Shanghai's profile, attracting talent/funding amid China's R&D push (GERD 2.55% GDP 2025).
Internal links to China higher ed opportunities highlight faculty/postdoc roles.
Challenges: Delivery, Ethics, Scalability
AAV limits (pre-existing immunity 30–50% Chinese pop); bystander edits need refinement. Ethical: Germline vs. somatic; equity in rare diseases. Solutions: Non-viral vectors, multiplex editors.
China's ethics framework (post-He Jiankui) ensures safety; trials monitor neurodevelopment longitudinally.
Global Ripple Effects and Future Therapies
Beyond SNIBCPS, applicable to 100+ chromatinopathies (e.g., CHD8 autism). Roadmap: Phase 1 trials 2027, scale to AAV9/NGEN variants. Shanghai's ecosystem—incubators, funding—accelerates.
Impacts: Reduced caregiver burden, workforce integration. For students: Biotech boom creates jobs in gene therapy.Career advice for gene editing researchers.
Career Opportunities in China's Gene Therapy Frontier
SJTU/Fudan seek postdocs in CRISPR/base editing; Shanghai hubs offer PhDs. With clinical trials ramping, demand surges for neuroscientists, vector engineers. Explore postdoc positions or university faculty roles in China.
Photo by Andrea Leopardi on Unsplash
This SJTU-led milestone underscores China's higher ed strength in translational biomed. As base editing matures, hope dawns for neurodevelopmental patients. Stay informed via higher ed news; check Rate My Professor for insights. For jobs, visit higher-ed-jobs or career advice.